News & Blog

Larimar Therapeutics Announces Three Poster Presentations at the 2024 International Congress for Ataxia Research (ICAR) on November 12–15, 2024

Webinar Recording: An Informational Webinar Hosted by Larimar Therapeutics — November 2024

Larimar Therapeutics Reports Several Updates on Nomlabofusp FA Program in Q2 2024 Operating and Financial Results

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

Nomlabofusp

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects with Friedreich’s Ataxia – CTI-1601

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

Larimar Therapeutics Receives FDA Clearance

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich’s Ataxia Trial and to Initiate Open Label Extension Trial

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort – First Quarter 2023 Financial Results